Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less then half the list price.
In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement.
READ ALSO: source=yahoofinance&utmmedium=organic”>Meta Focuses on New smart(er) Glasses
Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from president Donald Trump, who sent a letter to Novo last month demanding execu
Novo Nordisk Soars After Ozempic Alternative Approval and Promising Liver Treatment Data
Table of Contents
Novo nordisk, the Danish pharmaceutical giant, has seen its stock surge following the approval of a lower-cost version of its popular weight-loss drug, Ozempic, and positive clinical trial results for a novel liver disease treatment. These developments signal continued growth for the company as it dominates the rapidly expanding market for obesity and metabolic therapies.
Ozempic’s More affordable Cousin: Cagrisema
Novo Nordisk recently received approval from the European medicines Agency (EMA) for Cagrisema, a new formulation of semaglutide delivered via a tablet instead of an injection. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-ema-approves-oral-semaglutide-cagrisema-2024-07-19/ Cagrisema offers a more convenient and possibly more affordable alternative to Ozempic and Wegovy,both semaglutide-based injectables. While Ozempic is officially approved for type 2 diabetes, it’s widely used off-label for weight loss, driving critically important demand. Wegovy is specifically approved for weight management. The oral formulation is expected to broaden access to these medications, notably for patients who prefer or require a pill over an injection.
The company anticipates launching Cagrisema in Europe before the end of 2024. The FDA is currently reviewing Cagrisema for potential approval in the united States, wiht a decision expected in the coming months. https://www.novo-nordisk.com/news-and-media/news-and-press-releases/press-releases/2024/novo-nordisk-receives-positive-chmp-recommendation-for-cagrisema-oral-semaglutide/
promising Results in Non-alcoholic Steatohepatitis (NASH)
Beyond Cagrisema,Novo Nordisk announced highly encouraging Phase 3 trial results for resmetirom,an experimental drug targeting metabolic dysfunction associated with non-alcoholic steatohepatitis (NASH). https://www.novo-nordisk.com/news-and-media/news-and-press-releases/press-releases/2024/novo-nordisk-announces-positive-topline-results-from-phase-3-maestro-nashtransplant-trial-of-resmetirom/ NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation and damage, potentially leading to cirrhosis and liver failure.
The MAESTRO-NASH Transplant trial demonstrated that resmetirom considerably reduced the risk of liver transplant or death due to liver disease compared to a placebo. This is a major breakthrough, as currently, the onyl definitive treatment for end-stage NASH is a liver transplant. Novo Nordisk plans to submit these results to regulatory authorities, including the FDA, seeking approval for resmetirom.
Acquisition to Expand Treatment Options
Earlier this year, novo Nordisk’s competitor, Viking Therapeutics, saw its stock price surge after announcing positive data on a drug for NASH and also after an acquisition offer from a company called made. https://finance.yahoo.com/news/sending-biotechs-skyrocketed-244-173841449.html made intends to roll out MASH (Metabolic dysfunction-associated steatohepatitis) treatments.
Key Takeaways
Cagrisema Approval: Novo Nordisk secured EMA approval for Cagrisema,an oral semaglutide,offering a more accessible alternative to Ozempic and Wegovy.
Resmetirom Success: Phase 3 trial results for resmetirom in NASH show a significant reduction in the risk of liver transplant or liver-related death.
* Market Dominance: These developments reinforce novo Nordisk’s leading position in the expanding obesity and metabolic disease